Cero Therapeutics (CERO), a T cell therapy biotech, is open to licensing deals or a sale as it awaits data on its lead asset, CEO Chris Ehrlich tells Axios Pro. Cell therapy companies have been catching the eye of Big Pharma, Axios’ Katherine Davis notes.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CERO:
- CERo Therapeutics Updates Corporate Presentation on Innovations
- Cero doses third patient in starting dose cohort of Phase 1 CER-1236 trial
- Cero Therapeutics receives notice of allowance from USPTO for CER-1236
- Cero Therapeutics announces dose intensification in Phase 1 study of CER-1236
- CERo Therapeutics Gains Fast Track for AML Drug